[Management of myelodysplastic syndromes].
First Department of Internal Medicine, Nagoya University School of Medicine.
T
T
Hotta
D016025:Bone Transplantation; D002762:Cholecalciferol / Q000627:therapeutic use; D003115:Colony-Stimulating Factors / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003613:Danazol / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D006133:Growth Substances / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D015474:Isotretinoin / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000628:therapy*
D003115:Colony-Stimulating Factors; D006133:Growth Substances; D007155:Immunologic Factors; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D002762:Cholecalciferol; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D015474:Isotretinoin; D003613:Danazol